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The Grand Challenge for multiple scle-
rosis (MS) and Neuroimmunology in the 
21st century is to decipher the precise role 
played by the host immune system in MS 
and other neurologic diseases, and then use 
that knowledge to design effective immune-
mediated therapeutic strategies. This will be 
a very tall order, because in essence it means 
dissecting etiologies, and establishing treat-
ments for, a host of common and rare nerv-
ous system diseases. It is not out of the realm 
of possibility however, given the enormous 
strides being made in understanding how 
the nervous and immune systems interact.
The immune system is a complex mobile 
and reactive entity that performs surveillance 
on, and comes in contact with, every organ 
of the body. It can be modified and change 
over time. Knowledge about immune sys-
tem components and characteristics is con-
stantly evolving. Recent focus has been on 
understanding molecular communications, 
systems networks, and pathogen recogni-
tion receptors, and how their dysregulation 
can cause immune disturbances. Many of 
these concepts were unfamiliar just a few 
short years ago. Immunology taught dur-
ing medical and graduate school seems to 
become quickly outdated. As we learn more, 
the list of neurologic diseases in which the 
immune system plays an important role 
continues to grow. In light of the critical 
ties between the nervous and immune sys-
tems, every neurologist should understand 
current neuroimmunologic principles.
Disorders under the umbrella of 
Neuroimmunology are not just the pro-
totypic immune-mediated central (CNS) 
and peripheral nervous system (PNS) dis-
orders, such as MS and Myasthenia Gravis. 
There are also a host of novel syndromes. 
One example is Hashimoto’s encephalopa-
thy (Mocellin et al., 2007). This disorder, 
associated with normal thyroid function 
but very high antithyroid antibody titers, 
presents with dramatic neuropsychiatric 
and cognitive abnormalities, along with 
focal deficits, movement disorders, and 
seizures. It is important to recognize, since 
it is a corticosteroid-responsive encepha-
lopathy. Another example involves a spec-
trum of disorders resulting from immune 
reactivity to synapse components. They 
produce a wide variety of neuropsychiatric 
disturbances, characterized by catatonia, 
memory deficits, movement disorders, psy-
chosis, and seizures (Rosenfeld and Dalmau, 
2011). These disorders can affect children 
and young adults, in addition to older indi-
viduals. Unrecognized and untreated, these 
are devastating illnesses. With appropriate 
immunotherapy, even a moribund patient 
can make excellent recovery. Paraneoplastic 
disorders are yet another expanding neu-
roimmune area (Greenlee, 2010). They are 
defined as remote effects of malignancies, 
and can target virtually any site within the 
neuraxis (CNS, PNS, or neuromuscular 
junction). Typically there is a host immune 
response against one or more intracellular 
or cell membrane neuronal or glial anti-
gens, often marked by suggestive antibodies. 
These syndromes can present well before the 
neoplasm has declared itself. In most cases 
the paraneoplastic syndrome is so charac-
teristic that its recognition should trigger a 
tumor search. Therapy involves treating the 
associated malignancy, along with institu-
tion of immunotherapy. It is worth noting 
that virtually all major neurologic condi-
tions (including Alzheimer disease, cer-
ebrovascular disease, epilepsy, Parkinson’s, 
and CNS infection) are now recognized to 
have immune/inflammatory components. 
In fact, immunologic therapeutic strategies 
(such as anti-inflammatory agents, intrave-
nous immunoglobulins, monoclonal anti-
bodies, and vaccinations) are being tested 
in many of these disorders. This would have 
been unthinkable several years ago. It seems 
there is hardly a neurologic disease where 
Neuroimmunology is not involved. Recent 
studies even indicate that neuroimmune 
interactions control the generation of new 
functional neurons from neural stem cells 
(Molina-Holgado and Molina-Holgado, 
2010). This puts neuroimmune interven-
tions front and center when designing CNS 
repair strategies.
Multiple sclerosis remains the classic 
example of a CNS neuroimmune disorder. 
In the past few years knowledge about MS 
has advanced, with remarkable new insights. 
Yet these advances have also produced new 
questions and issues. MS is clearly not an 
inherited disease, although genetics play 
a key role and MS is recognized to be 
polygenic. The linked genes preferentially 
involve immune responses, cell adhesion, 
cell communications and signaling, and 
nervous system development (Wang et al., 
2011). Ongoing studies are aimed at iden-
tifying genes that facilitate development of 
MS, protect against it, and control disease 
severity. However, environmental factors 
appear to trump genetics. The implicated 
factors include vitamin D deficiency, clini-
cal Epstein Barr virus infection (mononu-
cleosis), tobacco use, lack of exposure to 
pathogens in early life, and most recently 
solar radiation (Ortor et al., 2011). How 
they influence development of MS needs 
to be determined.
Multiple sclerosis is now recognized to 
be heterogenous. It does not simply reflect T 
cells attacking myelin. B cells, chemokines, 
microglia, oxygen free radicals, and gluta-
mate are also implicated. MS is much more 
than just a demyelinating, white matter dis-
ease. Gray matter is involved early. There is 
neurodegeneration, with loss of axons and 
neurons, that seems to underlie the slow 
worsening progressive clinical subtype. 
Targets of attack have expanded beyond 
myelin and axon. The most recent topics of 
interest focus on glial cells; CNS ion chan-
nels, ion exchanges, and ion transporters; 
mitochondria; and blood vessels, including 
the venous system.
One of the most interesting areas of 
advancement in MS has been the deline-
ation of distinct neuroimmune disorders 
originally considered part of the MS spec-
trum: acute disseminated encephalomyelitis 
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Sjogren disease, a rheumatologic connective 
tissue disorder. The linkage likely reflects the 
fact that aquaporin 5 is a major component 
of salivary gland, and shows 50% homology 
with aquaporin 4. Sjogren disease itself can 
involve the CNS, and is in the differential 
diagnosis of MS. Perhaps this aquaporin 
link will prove key to explaining its CNS 
involvement.
For MS the Grand Challenge will be to 
understand disease etiology better (iden-
tify critical genes, environmental factors, 
heterogeneous damage mechanisms). This 
will allow as to develop an effective strat-
egy to treat the neurodegenerative progres-
sive phase of the disease. Right now this is 
a major gap, since the approved disease 
modifying therapies have only been shown 
to benefit relapsing forms of MS. MS awaits 
identification of meaningful biomarkers to 
guide treatment decisions. Finally, effective 
CNS repair strategies are needed. This will 
provide hope and assistance to patients with 
fixed deficits.
The Grand Challenge for 
Neuroimmunology in general will be to con-
tinue to identify those neurologic disorders 
in which the immune system plays a key role, 
and to develop effective therapeutic strate-
gies accordingly. Scientific advances are lead-
ing to amazing developments. Optogenetics, 
using viral vectors to insert light-sensitive 
channels in neurons, allows targeted neu-
rons to be turned on or off based on a simple 
light stimulus. Neural stimulation, depend-
ing on the CNS site, is being proposed to 
treat cognitive loss, depression, inability to 
walk, and obsessive compulsive disorder. It 
is exciting to look forward to understand-
ing, then controlling, the role of the immune 
system in neurologic disease.
(ADEM), and neuromyelitis optica (NMO)-
Devic disease. ADEM is a postinfectious or 
postvaccine encephalomyelitis that typi-
cally affects children, is monophasic, and 
produces a clinical syndrome of encepha-
lopathy accompanied by focal neurologic 
deficits. It is distinct from MS not just on 
clinical grounds, but also on neuroimaging, 
cerebrospinal fluid, and pathologic abnor-
malities, as well as etiology. Children with 
ADEM are at risk to go on to develop MS, 
in contrast to adults.
Not that long ago, NMO-Devic disease 
was also considered a variant of MS. It is 
now recognized that most patients have a 
unique neuroimmune disorder that reflects 
an immune attack against an astrocyte tar-
get, aquaporin 4 (Fujihara, 2011; Idiman 
and Ozalbas, 2011). Aquaporin 4 is a water 
channel component on the astrocyte foot 
process, and plays an important role in 
maintaining the blood brain barrier. IgG 
antibodies to aquaporin 4 have become an 
important diagnostic and prognostic bio-
marker. NMO-Devic disease also shows 
distinct etiology, pathology, neuroimaging, 
and CSF profiles from MS. It has a differ-
ent prognosis, and responds to different 
therapeutic approaches. That is why it is so 
crucial to differentiate NMO-Devic disease 
from MS. Study of NMO-Devic disease is 
producing new insights applicable to neu-
roimmune disorder, including MS. It has 
identified a new antigen target responsible 
for producing it, and a sensitive diagnostic 
biomarker antibody. It proves that astrocyte 
dysfunction can produce an inflammatory 
demyelinating CNS process. This provides 
a model to rethink MS. Could MS reflect 
a primary astrocyte disturbance? In addi-
tion, NMO-Devic disease has been linked to 
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